Basic information Safety Related Supplier

ChemicalBook Product Catalog Biochemical Engineering Biochemical Reagents Agonist Inhibitors Azeliragon

1/1

Azeliragon NEW

$33.00 2mg

$47.00 5mg

$80.00 10mg

Min. Order
Purity98.33%
Cas No603148-36-3
Supply Ability10g
Update time2026-04-13

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP6Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Azeliragon
CAS No	603148-36-3
EC-No
Min. Order
Purity	98.33%
Supply Ability	10g
Release date	2026/04/13

Product Introduction

Bioactivity

Name	Azeliragon
Description	Azeliragon (TTP488) is an antagonist at the Receptor for Advanced Glycation End products; is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer_acute_s disease (AD).
Kinase Assay	Recombinant Kinase Assays [1]: The ability of AZD5438 to inhibit cdk activity is examined using a scintillation proximity assay with recombinant cdk-cyclin complexes of cyclin-Ecdk2, cdk2-cyclin A, cdk4-cyclin D, and recombinant retinoblastoma substrate (amino acids 792-928) or cdk1-cyclin B1 with a peptide substrate derived from the in vitro p34cdc2 phosphorylation site of histone H1 (biotin-X-Pro-Lys-Thr-Pro-Lys-Lys-Ala-Lys-Lys-Leu). The activity of AZD5438 against recombinant cdk5/p25 (at 2 μM ATP) is determined in a scintillation proximity assay-based assay using peptide substrate (AKKPKTPKKAKKLOH). Inhibition of glycogen synthase kinase 3β activity is determined with scintillation proximity assay based on the use of human purified glycogen synthase kinase 3βenzyme and eukaryotic initiation factor 2B substrate (at 1 μM ATP). AZD5438 is screened against active recombinant human cdk6-cyclin D3, cdk7-cyclin H/MAT1 (cdk activating kinase complex), and cdk9-cyclin T using the kinase selectivity screening service.
Storage	Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMSO : 11 mg/mL (20.67 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.76 mM), Sonication is recommended.
Keywords	β-amyloid peptide \| βAmyloid \| β Amyloid \| TTP-488 \| TTP 488 \| RAGE \| PF-04494700 \| PF04494700 \| PF 04494700 \| Inhibitor \| inhibit \| BetaAmyloid \| Beta Amyloid \| bAmyloid \| b Amyloid \| Azeliragon \| Amyloid-β \| advancedglycationendproducts \| advanced glycation end products \| Abeta
Inhibitors Related	Benzenesulfonamide \| Deferoxamine Mesylate \| Ipriflavone \| HEPPS \| Phytic acid sodium salt \| Rutin \| Resveratrol \| 10-Undecenoic acid \| 2,4-Di-tert-butylphenol \| Chlorzoxazone \| Methyl tridecanoate \| Glimepiride
Related Compound Libraries	Failed Clinical Trials Compound Library \| Anti-Neurodegenerative Disease Compound Library \| Bioactive Compound Library \| Anti-Cancer Clinical Compound Library \| Drug Repurposing Compound Library \| CNS-Penetrant Compound Library \| Inhibitor Library \| Orally Active Compound Library \| Immunology/Inflammation Compound Library \| Bioactive Compounds Library Max \| Anti-Cancer Active Compound Library \| Anti-Cancer Drug Library

show more

Company Profile Introduction

You may like

Recommended supplier

Send Inquriy